2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. FGFR

FGFR

Fibroblast growth factor receptor

FGFR

Related Products

PDF 1.46 MB

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-50905S
    Dovitinib-d8
    		Inhibitor
    Dovitinib-d8 is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/Flt-1/VEGFR2/KDR/Flk-1/VEGFR3/Flt-4 and PDGFRα/PDGFRβ, respectively[1][2].
    Dovitinib-d<sub>8</sub>
  • HY-159691
    IONIS-FGFR4Rx
    		Inhibitor
    IONIS-FGFR4Rx (ISIS 463588) is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4), which is promising for research of renal diseases.
    IONIS-FGFR4Rx
  • HY-168653
    FGFR-IN-15
    		Inhibitor
    FGFR-IN-15 (compound 18i) is a pan-FGFR inhibitor with potently inhibitory activity against FGFR1-4..
    FGFR-IN-15
  • HY-163273
    FGFR4-IN-17
    		Inhibitor
    FGFR4-IN-17 (Compound (S)-23) is a piperazinyl diflurindan derivative containing pyridinyl. FGFR4-IN-17 is a FGFR inhibitor with IC50 values of 24.2, 16.1, 78.0, and 68.0 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FGFR4-IN-17 has antitumor activity.
    FGFR4-IN-17
  • HY-P990597
    HuGAL-F2
    		Inhibitor
    HuGAL-F2 is a human-derived antibody expressed in CHO cells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
    HuGAL-F2
  • HY-156791
    FGFR3-IN-7
    		Inhibitor
    FGFR3-IN-7 is a potent and selective FGFR3 inhibitor with IC50 value less than 350 nM. FGFR3-IN-7 can be used in research of cancer.
    FGFR3-IN-7
  • HY-160621
    CXF-009
    		Inhibitor
    CXF-009 is a selective and covalent FGFR4 inhibitor, with the IC50 of 48 nM. CXF-009 targeting Cys477 and Cys552 of FGFR4, and can be used for the study of hepatocellular carcinoma.
    CXF-009
  • HY-10331AR
    Regorafenib (monohydrate) (Standard)
    		Inhibitor
    Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/Flt-1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity.
    Regorafenib (monohydrate) (Standard)
  • HY-W801893
    FGFR1 inhibitor-13
    		Inhibitor
    FGFR1 inhibitor-13 (compound 1) is an FGFR1 inhibitor with an IC50 of 4.2 μM.
    FGFR1 inhibitor-13
  • HY-170776
    AXL/Angiokinase-IN-1
    		Inhibitor
    AXL/Angiokinase-IN-1 (compound 11b) is an AXL/triple angiokinase inhibitor, IC50=3.75 nM (AXL expression). AXL/Angiokinase-IN-1 inhibits epithelial-mesenchymal transition (EMT) in Bxpc-3, blocking lung cancer cell metastasis. AXL/Angiokinase-IN-1 also inhibits vascular and fibroblast functions, promoting apoptosis (apoptosis) in cancer cells and fibroblasts. AXL/Angiokinase-IN-1 features low toxicity and good metabolic stability.
    AXL/Angiokinase-IN-1
  • HY-158011
    FGFR3-IN-9
    		Inhibitor
    FGFR3-IN-9 (example27) is a selective FGFR3 inhibitor.
    FGFR3-IN-9
  • HY-151903S
    FGFR2/3-IN-1
    		Inhibitor
    FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC50s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC50s of 2.7 nM and 6.1 nM, respectively[1].
    FGFR2/3-IN-1
  • HY-50904S
    Nintedanib-d3
    		Inhibitor
    Nintedanib-d3 is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/Flt-1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib-d<sub>3</sub>
  • HY-147681
    SUN13837
    		Modulator
    SUN13837 is an orally active, potent and BBB-penetrated FGFR (fibroblast growth factor receptor) modulator. SUN13837 shows neuroprotective activity. SUN13837 can be used for neurodegenerative diseases research.
    SUN13837
  • HY-RS04923
    Fgfr4 Rat Pre-designed siRNA Set A
    		Inhibitor

    Fgfr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fgfr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Fgfr4 Rat Pre-designed siRNA Set A
    Fgfr4 Rat Pre-designed siRNA Set A
  • HY-163620
    LHQ490
    		Inhibitor
    LHQ490 is a selective FGFR2 inhibitor, with an IC50 of 5.2 nM. LHQ490 efficiently inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 1.4 nM. LHQ490 inhibits FGFR2-driven cancer cell proliferation and induces apoptosis of FGFR2-driven cancer cells.
    LHQ490
  • HY-156704
    FGFR4-IN-16
    		Inhibitor
    FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of FGFR-4 for cancer research.
    FGFR4-IN-16
  • HY-162283
    FGFR4-IN-18
    		Inhibitor
    FGFR4-IN-18 (compound 8z) is an inhibitor of FGFR4 and can be used in cancer research.
    FGFR4-IN-18
  • HY-N9507
    Picrasidine Q
    		Inhibitor
    Picrasidine Q, an alkaloid component extracted from Angelica keiskei species, has the capacity of anti-cell transformation and anti-cancer. Picrasidine Q induces cell apoptosis and G1 phase arrest in human esophageal cancer cell lines, and directly inhibits FGFR2 kinase activity.
    Picrasidine Q
  • HY-161841
    Antitumor agent-177
    		Inhibitor
    Antitumor agent-177 (compound 57), a non-steroidal NSC12 derivative, shows potent FGF2 binding affinity with a Kd of 24 μM by SPR. Antitumor agent-177 significantly inhibits the formation of HSPG/FGF2/FGFR1 ternary complexes. Antitumor agent-177 inhibits FGFR activation and exerts a potent anti-tumor activity on multiple myeloma (MM) cell lines in vitro and in vivo.
    Antitumor agent-177
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity